HLS Therapeutics Inc. (TSE:HLS - Free Report) - Equities researchers at Clarus Securities issued their Q3 2025 earnings per share (EPS) estimates for shares of HLS Therapeutics in a report released on Friday, August 15th. Clarus Securities analyst G. Ulybyshev expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share.
Separately, Raymond James Financial raised HLS Therapeutics from a "hold" rating to a "moderate buy" rating and increased their price objective for the company from C$5.00 to C$6.00 in a report on Thursday. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, HLS Therapeutics currently has a consensus rating of "Hold" and an average price target of C$5.00.
View Our Latest Stock Analysis on HLS Therapeutics
HLS Therapeutics Stock Down 0.8%
Shares of HLS traded down C$0.04 during mid-day trading on Monday, hitting C$5.22. 10,115 shares of the company's stock were exchanged, compared to its average volume of 12,564. The company has a market cap of C$116.13 million, a PE ratio of -5.23 and a beta of 1.07. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The company has a 50-day simple moving average of C$4.96 and a 200 day simple moving average of C$4.61. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.
About HLS Therapeutics
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access